Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Wednesday, March 19, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences presented promising preclinical data on PBGENE-DMD, a gene editing approach aimed at correcting the dystrophin gene for Duchenne Muscular Dystrophy (DMD). The treatment has the potential to benefit approximately 60% of DMD patients. Results indicated successful restoration of dystrophin protein expression and notable improvements in muscle function.
Price reaction · baseline $4.98 (2025-03-18 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Potential first-in-class gene editing approach for DMD.
Restored dystrophin protein expression in preclinical studies.
Significant improvement in muscle function observed.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Potential first-in-class gene editing approach designed for dystrophin gene correction leading the body to produce a functional dystrophin protein applicable for majority of DMD patients (up to ~60%) – PBGENE-DMD restored dystrophin protein expression and significantly improved muscle function
Frequently Asked Questions
What is PBGENE-DMD?
PBGENE-DMD is a gene editing approach designed to correct the dystrophin gene in DMD patients.
How many DMD patients could benefit from PBGENE-DMD?
Approximately 60% of DMD patients could potentially benefit from this treatment.
What were the results of the preclinical studies?
The studies showed restored dystrophin protein expression and significant improvements in muscle function.
Where was the data on PBGENE-DMD presented?
The data was presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference.